Moderna issues cost outlook amid revenue uncertainty; stock falls
FROM THE WIRE · FINANCE.YAHOO.COM
Moderna MRNA outlined its next phase of growth at its 2026 Analyst Day, highlighting oncology as a key long-term growth opportunity alongside efforts to improve the profitability of its infectious disease vaccine business. The update highlights Moderna's efforts to leverage its…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishCost expectations for 2027 with limited revenue visibility weigh on the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Moderna outlined its priorities at its 2026 Analyst Day.
- 02Shares fell after it outlined cost expectations for 2027.
- 03Oncology, including intismeran autogene with Merck, is a key growth lever.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Moderna, Inc.229.57 USD+0.51%today -0.77%Negative Merck & Co., Inc.146.28 USD+0.23%today -0.46%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets